医学と薬学 78/4 2021年4月号

出版社: 自然科学社
発行日: 2021-03-27
分野: 薬学  >  雑誌
ISSN: 03893898
雑誌名:
特集: 肝癌の新たな流れと治療の進歩
電子書籍版: 2021-03-27 (第1版第1刷)
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安:8~14営業日

2,200 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

1,540 円(税込)

目次

  • 特集 肝癌の新たな流れと治療の進歩

    序文
    脂肪肝由来の肝臓がんの特徴
    早期肝癌に対する肝切除とラジオ波焼灼術の前向き比較試験
    肝癌に対する粒子線治療(陽子線,重粒子線)
    肝癌に対する肝動脈化学塞栓療法と分子標的療法の役割分担
    進行肝癌に対する分子標的治療薬
    腫瘍マーカー・バイオマーカー・画像診断による薬物療法の効果判定
    免疫チェックポイント阻害剤を含む組み合わせ治療

    臨床試験
     ソリフェナシンコハク酸塩OD錠5mg「トーワ」の日本人健康成人男性における
      生物学的同等性試験

    研究
     新規心不全治療薬の予後改善機序とバイオマーカーによる評価

    Diagnosis
     SARS-CoV-2 Total抗体測定の意義
      ―VITROS-5600IIを用いての検討―
     Atellica IM免疫自動分析装置を用いた内分泌機能検査
      (甲状腺・性腺下垂体・副腎皮質機能)試薬の基礎的検討
     抗リン脂質抗体測定試薬「ステイシア MEBLuxテスト β2GPI」および
      「MESACUP-2テスト カルジオリピン」の基礎的性能および臨床的有用性の検討
     17-OHプロゲステロンELISA「DP」の基礎性能評価

    Health Care
     G-CEPTERの施術による自律神経系の機能,関節可動域,
      筋のこわばり,体表面温度の改善作用

    Cosmetic
     夜用オールインワンゲルの肌改善持続効果
     改良版目元クリームによるクマとたるみ,シワの改善効果
     酒粕添加の培養液による乳酸菌“sake lees KS” 発酵代謝産物が
      ヒアルロニダーゼ阻害活性におよぼす影響(第一報)

おすすめ商品

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

【特集 肝癌の新たな流れと治療の進歩】

P.346 掲載の参考文献
1) 日本消化器病学会, 日本肝臓学会 編 : NAFLD/NASH診療ガイドライン 2020 (改訂第2版), 南江堂, 東京, 2020.
2) Younossi ZM, Koenig AB, Abdelatif D, et al : Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64 : 73-84, 2016.
3) Li J, Zou B, Yeo YH, et al : Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019 : a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 4 : 389-398, 2019.
4) Estes C, Anstee QM, Arias-Loste MT, et al : Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol 69 : 896-904, 2018.
5) Tateishi R, Uchino K, Fujiwara N, et al : A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan : 2011-2015 update. J Gastroenterol 54 : 367-376, 2018.
6) Huang DQ, El-Serag HB, Loomba R : Global epidemiology of NAFLD-related HCC : trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2020. [Online ahead of print]
7) White DL, Kanwal F, El-Serag HB : Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10 : 1342-1359, 2012.
8) European Association for the Study of the Liver (EASL) ; European Association for the Study of Diabetes (EASD) ; European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64 : 1388-1402, 2016
9) 日本肝臓学会編 : 肝癌診療ガイドライン 2017年度版, 金原出版, 東京, 2017.
10) Kanwal F, Kramer JR, Mapakshi S, et al : Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology 155 : 1828-1837, 2018.
11) Yasui K, Hashimoto E, Komorizono Y, et al : Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol Hepatol 9 (5) : 428-433, 2011.
12) Romeo S, Kozlitina J, Xing C, et al : Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40 : 1461-1465, 2008.
13) Younossi Z, Anstee QM, Marietti M, et al : Global burden of NAFLD and NASH : trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15 : 11-20, 2018.
14) Unalp-Arida A, Ruhl CE : Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U. S. Population. Hepatology 71 : 820-834, 2020.
15) Angulo P, Kleiner DE, Dam-Larsen S, et al : Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 149 : 389-397.e310, 2015.
16) Hagstrom H, Nasr P, Ekstedt M, et al : Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 67 : 1265-1273 2017.
17) Chalasani N, Younossi Z, Lavine JE, et al : The diagnosis and management of nonalcoholic fatty liver disease : Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67 : 328-357, 2018.
18) Loomba R, Lim JK, Patton H, et al : AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease : Expert Review. Gastroenterology 158 : 1822-1830, 2020.
19) Nakamura J, Kamiya H, Haneda M, et al : Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001-2010 : Report of the Committee on Causes of Death in Diabetes Mellitus. J Diabetes Investig 8 : 397-410, 2017.
20) Alexander M, Loomis AK, van der Lei J, et al : Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnose in adults with diagnosed NAFLD : real-world study of 18 million patients in four European cohorts. BMC Med 17 : 95, 2019.
21) Zhang X, Harmsen WS, Mettler TA, et al : Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes. Hepatology 60 : 2008-2016, 2014.
22) Best J, Bechmann LP, Sowa JP, et al : GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 18 : 728-735.e4, 2020.
P.351 掲載の参考文献
1) 工藤正俊, 泉並木, 市田隆文, 他 : 第19回全国原発性肝癌追跡調査報告 (2006~2007) (日本肝癌研究会追跡調査委員会). 肝臓 57 : 45-73, 2016.
2) Ebara M, Ohto M, Sugiura N, et al : Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 5 : 616-626, 1990.
3) Yang B, Zan RY, Wang SY, et al : Radiofrequency ablation versus percutaneous ethanol injection for hepatocellular carcinoma : a meta-analysis of randomized controlled trials. World J Surg Oncol 13 : 96, 2015.
4) Nakashima T, Okuda K, Kojiro M, et al : Pathology of hepatocellular carcinoma in Japan. 232 Consecutive cases autopsied in ten years. Cancer 51 : 863-877, 1983.
5) Hasegawa K, Kokudo N, Imamura H, et al : Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 242 : 252-259, 2005.
P.362 掲載の参考文献
1) Lawrence TS, Robertson JM, Anscher MS, et al : Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 31 (5) : 1237-1248, 1995.
2) 櫻井英, 奥村敏, 水本斉 : 【放射線治療の現状と将来】粒子線治療の現状. Medical Science Digest 46 (13) : 800-803, 2020.
3) Kato H, Tsujii H, Miyamoto T, et al : Results of the first prospective study of carbon ion radiotherapy for hepatocellular carcinoma with liver cirrhosis. Int J Radiat Oncol Biol Phys 59 (5) : 1468-1476, 2004.
4) Chiba T, Tokuuye K, Matsuzaki Y, et al : Proton beam therapy for hepatocellular carcinoma : a retrospective review of 162 patients. Clin Cancer Res 11 (10) : 3799-3805, 2005.
5) Kawashima M, Furuse J, Nishio T, et al : Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 23 (9) : 1839-1846, 2005.
6) Komatsu S, Fukumoto T, Demizu Y, et al : Clinical results and risk factors of proton and carbon ion therapy for hepatocellular carcinoma. Cancer 117 (21) : 4890-4904, 2011.
7) Apisarnthanarax S, Bowen SR, Combs SE. Proton Beam Therapy and Carbon Ion Radiotherapy for Hepatocellular Carcinoma. Semin Radiat Oncol 28 (4) : 309-320, 2018.
8) Hong TS, Wo JY, Yeap BY, et al : Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34 (5) : 460-468, 2016.
9) Kasuya G, Kato H, Yasuda S, et al : Progressive hypofractionated carbon-ion radiotherapy for hepatocellular carcinoma : Combined analyses of 2 prospective trials. Cancer 123 (20) : 3955-3965, 2017.
10) Kim TH, Park JW, Kim BH, et al : Phase II Study of Hypofractionated Proton Beam Therapy for Hepatocellular Carcinoma. Front Oncol 10 : 542, 2020.
11) Parzen JS, Hartsell W, Chang J, et al : Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors : multi-institutional prospective results from the Proton Collaborative Group. Radiat Oncol 15 (1) : 255, 2020.
12) Fukuda K, Okumura T, Abei M, et al : Long-term outcomes of proton beam therapy in patients with previously untreated hepatocellular carcinoma. Cancer science 108 (3) : 497-503, 2017.
13) Lee CH, Hung SP, Hong JH, et al : How small is TOO small? New liver constraint is needed-Proton therapy of hepatocellular carcinoma patients with small normal liver. PloS one 13 (9) : e0203854, 2018.
14) Shibuya K, Ohno T, Terashima K, et al. Shortcourse carbon-ion radiotherapy for hepatocellular carcinoma : A multi-institutional retrospective study. Liver Int 38 (12) : 2239-2247, 2018.
15) Qi WX, Fu S, Zhang Q, et al : Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma : a systematic review and meta-analysis. Radiother Oncol 114 (3) : 289-295, 2015.
16) Hasan S, Abel S, Verma V, et al : Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma : practice patterns, outcomes, and the effect of biologically effective dose escalation. Journal of gastrointestinal oncology 10 (5) : 999-1009, 2019.
17) Sanford NN, Pursley J, Noe B, et al : Protons versus Photons for Unresectable Hepatocellular Carcinoma : Liver Decompensation and Overall Survival. Int J Radiat Oncol Biol Phys 105 (1) : 64-72, 2019.
18) Takamatsu S, Yamamoto K, Maeda Y, et al : Evaluation of Focal Liver Reaction after Proton Beam Therapy for Hepatocellular Carcinoma Examined Using Gd-EOB-DTPA Enhanced Hepatic Magnetic Resonance Imaging. PloS one 11 (12) : e0167155, 2016.
19) Chadha AS, Gunther JR, Hsieh CE, et al : Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiother Oncol 133 : 54-61, 2019.
20) Sugahara S, Oshiro Y, Nakayama H, et al : Proton beam therapy for large hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 76 (2) : 460-466, 2010.
21) Shibata S, Takamatsu S, Yamamoto K, et al : Proton Beam Therapy without Fiducial Markers Using Four-Dimensional CT Planning for Large Hepatocellular Carcinomas. Cancers 10 (3) : 71, 2018.
22) Kimura K, Nakamura T, Ono T, et al : Clinical results of proton beam therapy for hepatocellular carcinoma over 5cm. Hepatol Res 47 (13) : 1368-1374, 2017.
23) Sugahara S, Nakayama H, Fukuda K, et al : Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol 185 (12) : 782-788, 2009.
24) Kim DY, Park JW, Kim TH, et al : Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol 122 (1) : 122-129, 2017.
25) Komatsu S, Kido M, Asari S, et al : Particle radiotherapy, a novel external radiation therapy, versus liver resection for hepatocellular carcinoma accompanied with inferior vena cava tumor thrombus : A matched-pair analysis. Surgery 162 (6) : 1241-1249, 2017.
26) Sorin Y, Ikeda K, Kawamura Y, et al : Effectiveness of Particle Radiotherapy in Various Stages of Hepatocellular Carcinoma : A Pilot Study. Liver cancer 7 (4) : 323-334, 2018.
27) Bush DA, Smith JC, Slater JD, et al : Randomized Clinical Trial Comparing Proton Beam Radiation Therapy with Transarterial Chemoembolization for Hepatocellular Carcinoma : Results of an Interim Analysis. Int J Radiat Oncol Biol Phys 95 (1) : 477-482, 2016.
28) Shiba S, Shibuya K, Katoh H, et al : A comparison of carbon ion radiotherapy and transarterial chemoembolization treatment outcomes for single hepatocellular carcinoma : a propensity score matching study. Radiat Oncol 14 (1) : 137, 2019.
29) Kim TH, Koh YH, Kim BH, et al : Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma : a randomized phase trial. J Hepatol, 2020.
30) Tamura S, Okamura Y, Sugiura T, et al : A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma. Surg Today 50 (4) : 369-378, 2020.
31) Hashimoto T, Tokuuye K, Fukumitsu N, et al : Repeated proton beam therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 65 (1) : 196-202, 2006.
32) Komatsu S, Hori Y, Fukumoto T, et al : Surgical spacer placement and proton radiotherapy for unresectable hepatocellular carcinoma. World J Gastroenterol 16 (14) : 1800-1803, 2010.
33) Sasaki R, Demizu Y, Yamashita T, et al : First-In-Human Phase 1 Study of a Nonwoven Fabric Bioabsorbable Spacer for Particle Therapy : Space-Making Particle Therapy (SMPT). Adv Radiat Oncol 4 (4) : 729-737, 2019.
34) Kim TH, Park JW, Kim BH, et al : Optimal time of tumour response evaluation and effectiveness of hypofractionated proton beam therapy for inoperable or recurrent hepatocellular carcinoma. Oncotarget 9 (3) : 4034-4043, 2018.
35) 寺嶋千貴 : 【放射線照射後の画像診断】粒子線治療 (陽子線・炭素イオン線) による肝の限局性組織障害. 臨床放射線 61 (4) : 541-549, 2016.
P.369 掲載の参考文献
1) Llovet JM, Ricci S, Mazzaferro V, et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (4) : 378-390, 2008.
2) Bruix J, Qin S, Merle P, et al : Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (10064) : 56-66, 2017.
3) Kudo M, Finn RS, Qin S, et al : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial. Lancet 391 (10126) : 1163-1173, 2018.
4) Zhu AX, Kang YK, Yen CJ, et al : Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 (2) : 282-296, 2019.
5) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 (20) : 1894-1905, 2020.
6) Abou-Alfa GK, Meyer T, Cheng AL, et al : Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379 (1) : 54-63, 2018.
7) Lo CM, Ngan H, Tso WK, et al : Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable h epatocellular carcinoma. Hepatology 35 (5) : 1164-1171, 2002.
8) Llovet JM, Real MI, Montana X, et al : Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma : a randomised controlled trial. Lancet 359 (9319) : 1734-1739, 2002.
9) Llovet JM, Burroughs A, Bruix J : Hepatocellular carcinoma. The Lancet 362 (9399) : 1907-1917, 2003.
10) Bolondi L, Burroughs A, Dufour JF, et al : Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma : proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 32 (4) : 348-359, 2012.
11) Kudo M : Extremely High Objective Response Rate of Lenvatinib : Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma. Liver Cancer 7 (3) : 215-224, 2018.
12) Kudo M, Matsui O, Izumi N, et al : Transarterial chemoembolization failure/refractoriness : JSHLCSGJ criteria 2014 update. Oncology 87 (Suppl 1) : 22-31, 2014.
13) 日本肝臓学会編 : 肝癌診療マニュアル 第4版, pp.213-214, 医学書院, 東京, 2020.
14) Ogasawara S, Chiba T, Ooka Y, et al : Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology 87 (6) : 330-341, 2014.
15) Arizumi T, Ueshima K, Minami T, et al : Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma. Liver Cancer 4 (4) : 253-262, 2015.
16) Peck-Radosavljevic M, Raoul J-L, Lee HC, et al : OPTIMIS : An international observational study to assess the use of sorafenib after transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC). Journal of Clinical Oncology 32 (suppl 15) : TPS4155, 2014.
17) Arizumi T, Ueshima K, Iwanishi M, et al : Validation of a Modified Substaging System (Kinki Criteria) for Patients with Intermediate-Stage Hepatocellular Carcinoma. Oncology 89 (Suppl 2) : 47-52, 2015.
18) Kobayashi M : The development of novel molecular targeted agents change the treatment strategy and management paradigm for intermediate stage hepatocellular carcinoma. Kan-Tan-Sui 77 (2) : 325-331, 2018.
19) Kudo M, Han KH, Ye SL, et al : A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma : Asia-Pacific Primary Liver Cancer Expert Consensus Statements. Liver Cancer 9 (3) : 245-260, 2020.
20) Yamashita T, Kudo M, Ikeda K, et al : REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma : an analysis of Japanese subset. J Gastroenterol 55 (1) : 113-122, 2020.
21) 小林智, 森本学, 沼田和, 他 : BCLC stage B2またはB3の肝細胞癌に対するLenvatinibの多施設共同前向き観察研究の中間報告. 肝臓 61 (5) : 273-275, 2020.
22) Kudo M, Ueshima K, Aikata H, et al : Association Between Tumor Response by mRECIST and Overall Survival in Patients with Poorly Differentiated Hepatocellular Carcinoma (HCC) in REFLECT Study. Liver cancer 8 (suppl 1) : 90, 2019.
23) Kawamura Y, Kobayashi M, Shindoh J, et al : Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. Liver Cancer 9 (3) : 275-292, 2020.
24) Kudo M, Ueshima K, Chan S, et al : Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function : A Proof-Of-Concept Study. Cancers (Basel) 11 (8) : 1084, 2019.
25) Jain RK : Normalization of tumor vasculature : an emerging concept in antiangiogenic therapy. Science 307 (5706) : 58-62, 2005.
26) Kano MR, Komuta Y, Iwata C, et al : Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci 100 (1) : 173-180, 2009.
27) Kawamura Y, Kobayashi M, Shindoh J, et al : Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma. Liver Cancer 9 (6) : 756-770, 2020.
28) Kudo M, Ueshima K, Ikeda M, et al : Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma : TACTICS trial. Gut 69 (8) : 1492-1501, 2020.
P.375 掲載の参考文献
1) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 : 1894-1905, 2020.
2) Llovet JM, Villanueva A, Marrero JA, et al : Trial Design and Endpoints in Hepatocellular Carcinoma : AASLD Consensus Conference. Hepatology, 2020.
3) Marrero JA, Kulik LM, Sirlin CB, et al : Diagnosis, Staging, and Management of Hepatocellular Carcinoma : 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 68 : 723-750, 2018.
4) Llovet JM, Ricci S, Mazzaferro V et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 24 : 378-390, 2008.
5) Kudo M, Finn RS, Qin S, et al : Lenvatinib versus sorafenib in first-line treatment of patients with randomised phase 3 non-inferiority trial. Lancet 391 : 1163-1173, 2018.
6) Raoul JL, Kudo M, Finn RS, et al : Systemic therapy for intermediate and advanced hepatocellular carcinoma : Sorafenib and beyond. Cancer Treat Rev 68 : 16-24, 2018.
7) Kuzuya T, Asahina Y, Tsuchiya K, et al : Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology 81 : 251-258, 2011.
8) Kuzuya T, Ishigami M, Ishizu Y, et al : Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS One 10 : e0138776, 2015.
9) Otsuka T, Eguchi Y, Kawazoe S, et al : Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res 42 : 879-886, 2012.
10) Kuzuya T, Ishigami M, Ishizu Y, et al : Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma. Oncology 91 : 261-266, 2016.
11) Kuzuya T, Ishigami M, Ito T, et al : Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma. Hepatol Res 50 : 374-381, 2020.
12) Takahashi A, Moriguchi M, Seko Y, et al : Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma. Anticancer Res 39 : 5149-5156, 2019.
13) Maruta S, Ogasawara S, Ooka Y, et al : Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 9 : 382-396, 2020.
14) Kuzuya T, Ishigami M, Ito T, et al : Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. Anticancer Res 40 : 2283-2290, 2020.
15) Tanaka T, Kuzuya T, Ishigami M, et al : Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Oncology 98 : 621-629, 2020.
16) Bruix J, Qin S, Merle P, et al : RESORCE Investigators : Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 : 56-66, 2017.
17) Zhu AX, Kang YK, Yen CJ, et al : Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 : 282-296, 2019.
18) Finn RS, Merle P, Granito A, et al : Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC : Additional analyses from the phase III RESORCE trial. J Hepatol 69 : 353-358, 2018.
19) Kuzuya T, Ishigami M, Ito T, et al : Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment. Hepatol Res 49 : 1054-1065, 2019.
20) Kuzuya T, Ishigami M, Ishizu Y, et al : Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment. Oncology 95 : 91-99, 2018.
21) Kuzuya T, Ishigami M, Ito T, et al : Initial experience of ramucirumab treatment after lenvatinib failure for patients with advanced hepatocellular carcinoma. Anticancer Res 40 : 2089-2093, 2020.
22) Abou-Alfa GK, Meyer T, Cheng AL, et al : Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379 : 54-63, 2018.
P.383 掲載の参考文献
1) Llovet JM, Ricci S, Mazzaferro V, et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (4) : 378-390, 2008.
2) Cheng AL, Kang YK, Chen Z, et al : Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma : a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (1) : 25-34, 2009.
3) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med 382 (20) : 1894-1905, 2020.
4) Kudo M, Finn RS, Qin S, et al : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial. Lancet 391 (10126) : 1163-1173, 2018.
5) Bruix J, Qin S, Merle P, et al : Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (10064) : 56-66, 2017.
6) Zhu AX, Kang YK, Yen CJ, et al : Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20 (2) : 282-296, 2019.
7) Abou-Alfa GK, Meyer T, Cheng AL, et al : Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. N Engl J Med 379 (1) : 54-63. 2018.
8) Kawaoka T, Ando Y, Yamauchi M, et al : Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. Hepatol Res 50 (7) : 885-888, 2020.
9) Marabelle A, Le DT, Ascierto PA, et al : Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer : Results From the Phase II KEYNOTE-158 Study. J Clin Oncol 38 (1) : 1-10, 2020.
10) Kudo M, Ueshima K, Yokosuka O, et al : Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS) : a randomised, open label, phase 3 trial. Lancet Gastroenterol Hepatol 3 (6) :424-432, 2018.
11) Kudo M, Ueshima K, Chiba Y, et al : Objective Response by mRECIST Is an Independent Prognostic Factor for Overall Survival in Hepatocellular Carcinoma Treated with Sorafenib in the SILIUS Trial. Liver Cancer 8 (6) : 505-519, 2019.
12) Eisenhauer EA, Therasse P, Bogaerts J, et al : New response evaluation criteria in solid tumours : revised RECIST guideline (version 1.1). Eur J Cancer 45 (2) : 228-247, 2009.
13) Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 (1) : 52-60, 2010.
14) Kaneko S, Tsuchiya K, Yasui Y, et al : Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. JGH Open 4 (6) : 1183-1190, 2020.
15) Llovet JM, Montal R, Villanueva A : Randomized trials and endpoints in advanced HCC : Role of PFS as a surrogate of survival. J Hepatol 70 (6) : 1262-77, 2019.
16) Park HJ, Kim KW, Pyo J, et al : Incidence of Pseudoprogression during Immune Checkpoint Inhibitor Therapy for Solid Tumors : A Systematic Review and Meta-Analysis. Radiology 297 (1) : 87-96, 2020.
17) Shao YY, Lin ZZ, Hsu C, et al : Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 116 (19) : 4590-4596, 2010.
18) Shao YY, Liu TH, Hsu C, et al : Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma. Liver Int 39 (11) : 2184-2189, 2019.
19) Chan SL, Mo FK, Johnson PJ, et al : New utility of an old marker : serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27 (3) : 446-452, 2009.
20) Arai T, Kobayashi A, Ohya A, et al : Assessment of treatment outcomes based on tumor marker trends in patients with recurrent hepatocellular carcinoma undergoing trans-catheter arterial chemo-embolization. Int J Clin Oncol 19 (5) : 871-879, 2014.
21) Murata K, Suzuki H, Okano H, et al : Hypoxia-induced des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 36 (1) : 161-170, 2010.
22) Schoenleber SJ, Kurtz DM, Talwalkar JA, et al : Prognostic role of vascular endothelial growth factor in hepatocellular carcinoma : systematic review and meta-analysis. Br J Cancer 100 (9) : 1385-1392, 2009.
23) Tsuchiya K, Asahina Y, Matsuda S, et al : Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. Cancer 120 (2) : 229-237, 2014.
24) Llovet JM, Pena CE, Lathia CD, et al : Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 18 (8) : 2290-2300, 2012.
25) Arao T, Ueshima K, Matsumoto K, et al : FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 57 (4) : 1407-1415, 2013.
26) Kaibori M, Sakai K, Ishizaki M, et al : Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment. Oncotarget 7 (31) : 49091-49098, 2016.
27) Tahara M, Schlumberger M, Elisei R, et al : Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer 75 : 213-221, 2017.
28) Shigesawa T, Suda G, Kimura M, et al : Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. JGH Open 4 (5) : 880-888, 2020.
29) Chuma M, Uojima H, Numata K, et al : Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers (Basel) 12 (2) : 293, 2020.
30) Myojin Y, Kodama T, Maesaka K, et al : ST6GAL1 Is a Novel Serum Biomarker for Lenvatinib-Susceptible FGF19-Driven Hepatocellular Carcinoma. Clin Cancer Res 27 (4) :1150-1161, 2021.
31) Ferrucci PF, Ascierto PA, Pigozzo J, et al : Baseline neutrophils and derived neutrophil-to-lymphocyte ratio : prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 27 (4) : 732-738, 2016.
32) Weide B, Martens A, Hassel JC, et al : Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. Clin Cancer Res 22 (22) : 5487-5496, 2016.
33) Music M, Iafolla MAJ, Ren AH, et al : Serum PD-1 Is Elevated after Pembrolizumab Treatment but Has No Predictive Value. Mol Cancer Ther 18 (10) : 1844-1851, 2019.
P.392 掲載の参考文献
1) Llovet JM, Ricci S, Mazzaferro V, et al : Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (4) : 378-390, 2008.
2) Finn RS, Qin S, Ikeda M, et al : Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N E J Med 382 : 1894-1905, 2020.
3) Sangro B, Park JW, Dela Cruz CM, et al : A randomized, multicenter, phase 3 study of nivolumab versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma : checkmate 459. J Clin Oncol 34 (suppl 15) : TPS4147, 2016.
4) Finn RS, Ryoo BY, Merle P, et al : Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240 : a randomized, double-blind, phase III trial. J Clin Oncol 38 : 193-202, 2020.
5) Kudo M, Finn RS, Qin S, et al : Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma : a randomised phase 3 non-inferiority trial. Lancet 391 (10126) : 1163-1173, 2018.
6) Finn RS, Qin S, Ikeda M, et al : EASL DLCS 2021 #O-05
7) Kudo M, Ueshima K, Ikeda M, et al : Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma : TACTICS trial. Gut 69 (8) : 1492-1501, 2020.
8) Hiraoka A, Kumada T, Atsukawa M, et al : Important Clinical Factors in Sequential Therapy Including Lenvatinib against Unresectable Hepatocellular Carcinoma. Oncology 97 (5) : 277-285, 2019.
9) Fujimoto D, Yoshioka H, Kataoka Y, et al : Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy. J Thorac Oncol 14 (3) : 468-474, 2019.
10) Champiat S, Dercle L, Ammari S, et al : Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1. Clin Cancer Res 23 (8) : 1920-1928, 2017.
11) Voron T, Marcheteau E, Pernot S, et al : Control of the immune response by pro-angiogenic factors. Front Oncol 4 : 70, 2014.
12) Chen DS, Mellman I : Oncology meets immunology : the cancer-immunity cycle. Immunity 39 (1) : 1-10, 2013.
13) Pinyol R, Sia D, Llovet JM : Immune exclusion-Wnt/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res 25 (7) : 2021-2023, 2019.
14) Lee MS, Ryoo BY, Hsu CH, et al : Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (GO30140) : an open-label, multi-centre, phase 1b study. The Lancet Oncology 21 : 808-820, 2020.
15) Finn RS, Ikeda M, Zhu AX, et al : Phase Ib study of Lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma. J Clin Oncol 38 (26) : 2960-2970, 2020.
16) Yau T, Kang YK, Kim TY, et al : Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC) : Results from CheckMate 040. J Clin Oncol 37 (15_suppl) : 4012, 2019.
17) Finn RS, Ikeda M, Galle PR et al : IMbrave 150 : updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) + bevacizumab (beva) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 39 (suppl 3), 2021.

【臨床試験】

P.406 掲載の参考文献
1) ベシケア錠2.5mg, ベシケア錠5mg, ベシケアOD錠2.5mg, ベシケアOD錠5mgの医薬品添付文書 (2019年8月改訂〔第1版〕) (アステラス製薬株式会社)
2) 後発医薬品の生物学的同等性試験ガイドライン (平成9年12月22日 医薬審第487号〔平成13年5月31日 医薬審発第786号, 平成18年11月24日 薬食審査発第1124004号, 平成24年2月29日 薬食審査発0229 第10号にて一部改正〕).
3) 奥田豊 : RACTAB(R) 技術を活用したOD錠の製剤設計. 薬剤学 71 (1) : 21, 2011.
4) 医薬品の臨床試験の実施の基準に関する省令 (平成9年3月27日 厚生省令第28号〔平成15年6月12日 厚生労働省令第106号, 平成16年12月21日 厚生労働省令第172号, 平成18年3月31日 厚生労働省令第72号, 平成20年2月29日 厚生労働省令第24号, 平成24年12月28日 厚生労働省令第161号, 平成28年1月22日 厚生労働省令第9号にて一部改正〕).

【研究】

P.416 掲載の参考文献
1) McMurray JJ, et al : PARADIGM-HF Investigators Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014.
2) Armstrong PW, et al : Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 382 : 1883-1893, 2020.
3) Swedberg K, et al : SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomized placebo-controlled study. Lancet 376 : 875-885, 2010.
4) 蔦本尚慶 : sGS活性化薬vericiguatを用いたVICTORIA研究結果と解釈について. 医学と薬学 77 (10) : 1427-1437, 2020.
5) McMurray JJ, et al : Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med 381 : 1995-2008, 2019.
6) Kiuchi S, et al : Long-term use of ipragliflozin improved cardiac sympathetic nerve activity in a patient with heart failure. Drug Discov Ther 12 : 51-54, 2018.
8) Ibrahim NE, et al : Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients. Clin Chem 67 : 79-86, 2021.
9) Tsutamoto T, et al : Relationship between left ventricular preload and N-terminal pro-brain natriuretic peptide in obese patients. J Cardiol 76 : 580-584, 2020.
10) Tsutamoto T, et al. Renal clearance of N-terminal pro-prain natriuretic peptide is markedly decreased in chronic kidney disease. Circ Rep 8 : 326-332, 2019.
12) Tsutamoto T, et al : Heart is the Target Organ of Endogenous Cardiac Natriuretic Peptid. Int Heart J 61 : 77-82, 2020.

【Diagnosis】

P.427 掲載の参考文献
1) COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
2) Peng Zhou, Xing-LouYang, Xian-Guang Wang, et al : A pneumonia outbreakassociated with a new coronavirus of probable bat origin. Nature 579 (7798) : 270-273, 2020.
3) 国立感染症研究所の病原体検出マニュアル新型コロナウイルス感染症 病原体検出マニュアル, Ver. 2.9.1, 2020. https://www.niid.go.jp/niid/images/lab-manual/2019-nCoV20200304v2.2019-nCoV
4) Bastos M L, Tavaziva G, Abidi S K, et al : Diagnostic accuracy of serological tests for covid-19 : systematic review and meta-analysis. BMJ 370 : m2516, 2020.
5) Fujigaki H, Takemura M, Osawa M, et al : Reliability of serological tests for COVID-19 : comparison of three immunochromatography test kits for SARS-CoV-2 antibodies. Heliyon 6 (9) : e04929, 2020.
6) U. S. Food and Drug Administration (FDA) : Virtual Town Hall Series-Coronavirus (COVID-19) Test Development and Validation OCTOBER 21, 2020. https://www.fda.gov/emergency-preparednessand-response/counterterrorism-and-emergingthreats/coronavirus-disease-2019-covid-19
7) 藤垣英嗣, 竹村正男, 大澤道子, 他 : 全自動免疫生化学統合システムVITROSによるSARS-CoV-2 IgG抗体測定の基礎的検討. 医学と薬学 78 (3) : 281-288 2021.
8) Report of clustering pneumonia of unknown etiology in Wuhan City. Wuhan Municipal Health Commission, China 2019. http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989
9) Na Zhu, Dingyu Zhang, Wenling Wang : A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med 382 : 727-733, 2020.
10) Sakurai A, Sasaki T, Kato S, et al : Natural History of Asymptomatic SARS-CoV-2 Infection. N Engl J Med 383 : 885-886, 2020.
11) Mancuso P, Venturelli F, Vicentini M, et al : Temporal profile and determinants of viral shedding and of viral clearance confirmation on nasopharyngeal swabs from SARS-CoV-2-positive subjects : a populationbased prospective cohort study in Reggio Emilia, Italy. BMJ Open 10 : e040380, 2020.
12) Yunbao Pan, Xinran Li, Gui Yang, et al : Serological immunochromatograpic approach in diagnosis with SARS-CoV-2 infected COVID-19 patients. J Infect 81 (1) : e28-e32, 2020.
P.445 掲載の参考文献
1) Yallow RS, Berson SA : Immunoassay of endogenous plasma insulin in man. J Clin. Invest 39 : 1157-1175, 1960.
2) 糸賀仁美, 河内一恋, 畑伸顕, 他 : Atellica Solutionを用いたTSH, FT4, FT3, 抗TPO抗体および抗Tg抗体測定の基礎的性能評価. 医学と薬学 76 (5) : 699-712, 2019.
3) 糸賀仁美, 河内一恋, 畑伸顕, 他 : Atellica Solutionを用いたFSH, LH, PRL, E2, hCG, DHEA-S, PTH, IgE, コルチゾールおよびテストステロン測定の基礎的性能評価. 医学と薬学 76 (7) : 1011-1038, 2019.
4) 相本利帆, 奥原俊彦 : Atellica Solution「TSH3UL」キットの基礎的検討 : 日本臨床検査自動化学会会誌 44 (4) : 476-476, 2019.
5) 川崎芳正, 荻原貴裕 : ADVIA Centaur (ケンタウルス) を用いた, 血清TSH値, FT4値, およびFT3値に関する基礎的検討. 医学と薬学 63 (2) : 325-329, 2010.
6) 川崎芳正 : ADVIA Centaur (ケンタウルス) を用いた甲状腺ホルモン (FT3・FT4) とTSHの基礎的検討. 生物試料分析 23 (2) : 63-68, 2000.
7) 上條桂一, 川崎芳正, 樋口義典 : Centaur (CHIRON社) を用いた血清TSH値, FT3値, FT4値, T3値, T4値およびT3摂取率 (T3U) の基礎的・臨床的検討. 医学と薬学 40 (2) : 387-394, 1998.
8) 上條桂一, 有岡広紀, 川崎芳正 : Bayer Medical社のケミルミACS-NEW-抗TPO抗体キットを用いた抗甲状腺ペルオキシダーゼ抗体 (TPOAb) 測定に関する基礎的・臨床的検討. 医学と薬学 50 (6) : 871-877, 2003.
P.459 掲載の参考文献
1) Hughes GR, Harris NN, Gharavi AE : The anticardiolipin syndrome. J Rheumatol 13 (3) : 486-489, 1986.
2) Ruiz-Irastorza G, Crowther M, Branch W, et al : Antiphospholipid syndrome. Lancet 376 (9751) : 1498-1509, 2010.
3) Miyakis S, Lockshin MD, Atsumi T, et al : International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2) : 295-306, 2006.
4) 難病情報センターホームページ (2021年2月現在) からの転載 https://www.nanbyou.or.jp/entry/4102
5) 大友耕太郎, 渥美達也 :抗リン脂質抗体測定の意義. 日本臨床免疫学会会誌 36 (2) : 63-70, 2013.
6) 奥健志 :抗リン脂質抗体症候群における血栓症リスクのスコア化. 日本臨床免疫学会会誌 40 (6) : 435-441, 2017.
7) 奥健志, 久田諒, 大村一将, 他 : 完全自動化測定器による抗リン脂質抗体測定の意義. 日本臨床免疫学会会誌 38 (3) : 157-163, 2015.
8) アイエルジャパン株式会社, 日本臨床検査医学会臨床検査点数委員会 : 令和2年より適用の新規保険収載検査項目の解説. 臨床病理 68 (10) : 866-868, 2020.
9) 岡田純, 渡辺清明, 山本美保子, 他 : MESACUPカルジオリピンテストの有用性. 医学と薬学 36 (6) : 1389-1394, 1996.
10) 鏑木淳一, 大矢和彦 : IgM抗カルジオリピン抗体を測定する酵素免疫測定法 (ELISA) の開発とその臨床的有用性. 医学と薬学 43 (6) : 1183-1188, 2000.
11) Harris EN, Gharavi AE, Patel SP, et al : Evaluation of the anti-cardiolipin antibody test : report of an international workshop held 4 April 1986. Clin Exp Immunol 68 (1) : 215-222, 1987.
12) Ichikawa K, Tsutsumi A, Atsumi T, et al : A chimeric antibody with the human γ1 constant region as a putative standard for assays to detect IgG β2-glycoprotein I-dependent anticardiolipin and anti-β2-glycoprotein I antibodies. Arthritis Rheum 42 (11) : 2461-2470, 1999.
13) Ichikawa K, Khamashta MA, Koike T, et al : beta 2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome. Arthritis Rheum 37 (10) : 1453-1461, 1994.
14) James FP, Jeffrey EV, A Paul D, et al : Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures ; Approved Guideline-Second Edition. Clinical and Laboratory Standards Institute : CLSI : document EP17-A2, 2012.
15) 本木由香里, 野島順三, 吉田美香, 他 : ELISAによる抗リン脂質抗体価測定の標準化に向けて. 日本血栓止血学会誌 27 (6) : 644-652, 2016.
16) 原和冴, 本木由香里, 金重理沙, 他 : Multiplex-EIA systemを利用した抗リン脂質抗体スクリーニング検査システムの検討. 医学検査 69 (2) : 160-167, 2020.
P.466 掲載の参考文献
1) 税所純敬, 豊浦多喜雄, 下澤和彦, 他 : 血清17-OHP濃度の測定-マススクリーニングにおけるDPC 17α-OHプロゲステロンキットの応用-. 医学と薬学 24 (3) : 633-637, 1990.
2) 日本小児内分泌学会 マス・スクリーニング委員会日本マス・スクリーニング学会 : 21-水酸化酵素欠損症の診断・治療のガイドライン (2014年改訂版)
3) 日本内分泌学会, 日本小児内分泌学会, 日本ステロイドホルモン学会, 厚生労働科学研究費補助金政策研究事業「副腎ホルモン産生異常に関する調査研究」班合同作成 : 副腎クリーゼを含む副腎皮質機能低下症の診断と治療に関する指針. 日本内分泌学会雑誌 91 (Suppl) : 1-72, 2015.

【Health Care】

P.475 掲載の参考文献
1) 厚生労働省 : 平成29年患者調査の概況. 平成29年.
2) 厚生労働省 : 2019年 国民生活基礎調査の概況. 令和元年.
3) 厚生科学審議会地域保健健康増進栄養部会, 次期国民健康づくり運動プラン策定専門委員会 : 健康日本21 (第二次) の推進に関する参考資料. 平成24年7月.
4) 厚生科学審議会地域保健健康増進利用部会 : 健康日本21 (第二次) 」中間報告. 平成30年9月.
5) 柳井久江 : 4 Stepsエクセル統計 第4版. オーエムエス出版, 東京, 2015.
6) 森英俊 : 運動・からだ図解 経絡・ツボの基本. マイナビ出版, 東京, 2014.
7) 伊藤剛 : カラダを考える東洋医学. 朝日新聞出版, 東京, 2018.
8) 井草理江, 青木健, 亀田真美, 他 : 介護ケアとしての足部マッサージ中および終了後における自律神経活動指標の変化. 日本看護研究学会雑誌 31 (5) : 21-27, 2008.
9) 菅原清子, 堀口寛子, 沖田善光, 他 : 足つぼ指圧中の自律神経活動と脳波変化の検討. 電子情報通信学会技術研究報告. MBE, MEとバイオサイバネティックス 105 (456) : 57-60, 2005.
10) 田村幸恵, 鈴木玲子 : 手指への指圧によるリラクゼーションション効果の検討. 保健医療福祉科学 3 : 39-45, 2013.
11) 佐藤都也子 : 健康な成人女性におけるハンドマッサージの自律神経活動および気分の影響. 山梨大学看護学会誌 4 (2) : 25-32, 2006.
12) 新田紀枝, 阿曽洋子, 川端京子 : 足浴, 足部マッサージ, 足浴後マッサージによるリラクゼーション反応の比較. 日本看護科学会誌 22 (3) : 55-63, 2002.
13) 菊池真, 青野都, 石川恵子, 他 : 指圧および経穴マッサージが体温と身体柔軟性に及ぼす効果. 日本伝統医療看護連携学会誌 1 (1) : 57-64, 2020.
14) 古田高征 : 押圧刺激が組織硬度や主観的感覚におよぼす影響. 日本東洋医学系物理療法学会誌 43 (2) : 73-78, 2018.
15) 松本勅, 今枝美和, 井上基浩 : 手部経穴 (合谷, 後渓, 落枕) 置鍼による頸部可動域の変化. 全日本鍼灸学会雑誌 67 (1) : 23-28, 2017.
16) 高橋秀則 : 経穴刺激療法 (遠絡療法) が有用であった重度多発関節痛の1症例. 日本ペインクリニック学会誌 27 (1) : 65-69, 2020.
17) 安藤讓二, 是永理佐, 山本希美子, 他 : 生体テンセグリティ : 新しい構造生成原理. BME 14 (8) : 11-16, 2000.

【Cosmetic】

P.482 掲載の参考文献
1) 岡田明大 : スキンケア化粧品の快い使い心地感が心拍変動性と脳波に及ぼす影響. 日本生理人類学会誌 4 (3) : 147-153, 1999.
2) 佐藤智穂 : 化粧品使用時の感情と意識の変化. 日本化粧品技術者会誌 54 (4) : 351-357, 2020.
3) 厚生労働省 : 令和元年国民健康・栄養調査結果の概要. pp.27, 2020.
4) 石川正, 大梛進 : 口唇形状の検討-面積測定による評価-. 昭医会誌 56 (5) : 107-113, 2018.
5) 開原典子, 高田暁 : デスクワーク中の室内温湿度変化に伴う皮膚含水率の実態調査. 第37回人間-生活環境系シンポジウム (人間-生活環境系学会) D-1, 2013.
6) 田上八朗 : 保湿製品と角層水分量. 皮膚病診療 12 : 202-206, 1990.
7) 武村俊之 : 保湿製剤の効用-角層の保湿機構. ファルマシア 28 (1) : 61-95, 1992.
8) 外岡憲明 : ヒアルロン酸ナトリウムの保湿性. 皮膚 27 (2) : 296-302, 1985.
9) 酒井康夫 : 皮膚浸透性コラーゲン・トリペプチド (CTP) の機能性と有用性. 日本写真学会誌 67 (4) : 397-401, 2004.
10) 尾沢達也, 西山聖二, 堀井和泉他 : 皮膚保湿における保湿剤の働き. 皮膚 27 (2) : 276-298, 1985.
11) 三木聡子, 漆畑 修, 福田美和他 : 皮膚弾力測定による肌年齢の算出. 日本皮膚科学会誌 114 (3) : 657, 2004.
12) Pierard G E, Henry F, Castelli D, et al : Aging and rheological properties of facial skin in women. Gerontology 44 : 159-161, 1998.
13) Hyo S R, Young J, Sun O, et al : Influence of age and regional difference on skin elasticity as measured by the Cutometer. Skin Res Technol 14 : 354-358, 2008.
14) Beak J H, Lee M Y, Koh J S : Relationship between clinical features of facial dry skin and biophysical parameters in Asians. J Cosmet Sci 33 : 222-227, 2011.
15) Hara M, Ma T, Verkman A S : Selectively reduced glycerol in skin of aquaporin-3-deficient mice may account for impaired skin hydration, elasticity, and barrier recovery. J Biol Chem 277 : 46616-46621, 2002.
P.489 掲載の参考文献
1) 平徳久, 押田至雅, 勝山雄志, 他 : 新規ビタミンC誘導体 "ミリスチルグリセリルアスコルビン酸" の乳化性能と有効性. FRAGRANCE JOURNAL 43 (3) : 30-33, 2015
2) 和田優, 勝山雄志, 中村清香, 他 : コラーゲン産生を促進するコラーゲン由来のエイジングケア成分. FRAGRANCE JOURNAL 46 (1) : 35-40, 2018.
3) 浜田祥男, 福勢元 :抗シワ素材としてのビタミンAおよびその誘導体. FRAGRANCE JOURNAL 26 (4) : 75-77, 1998.
P.495 掲載の参考文献
1) Tsutsui N, Yamamoto Y, Iwami K : Protein-Nutritive Assessment of Sake Lees Obtained by Brewing from Liquefied Rice. Nutr Sci Vitaminol 44 : 177-186, 1998.
2) Tanaka N : Methodology of the isolation of lactic acid bacteria strains. Jpn J Lactic Acid Bact 30 (1) : 3-7, 2019.
3) Amann RI, Ludwig W, Schleifer KH : Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbiol Rev 59 : 143-169, 1995.
4) Altschul SF, Madden TL, Schaffer AA, et al : Gapped BLAST and PSI-BLAST : a new generation of protein database search programs. Nucleic Acids Res 25 (17) : 3389-3402, 1997.
5) Mayer, K, Dobos R, Smith EM : THE HYDROLYSIS OF THE POLYSACCHARIDE ACIDS OF VITREOUS HUMOR, OF UMBILICAL CORD, AND OF STREPTOCOCCUS BY THE AUTOLYTIC ENZYME OF PNEUMOCOCCUS. J Biol Chem 118 : 71-78, 1937.
6) Katsuta M : Effect of Administered Ethyl lcosapentate and Clofibrate on Serum and Liver Phospholipid in Mice. Jpn J Med Pharm Sci 48 (6) : 967-975, 2002.
7) Katsuta M : Effects of anti-hyperlipidemics on the fatty acid composition of free fatty acid and phospholipids in mouse serum. Jpn Pharmacol Ther 31 (9) : 767-771, 2003.
8) Katsuta M, Nomura H : Effects of Administered Antihyperlipidemic Drugs on Phospholipids and the Composition of Free Fatty Acids in Mouse Liver. Jpn J Med Pharm Sci 49 (2) : 225-232, 2003.
9) 近藤紗代, 高橋俊成, 渡辺敏郎, 他 : 生もと乳酸菌米発酵液が皮膚に及ぼす影響. フレグランスジャーナル 42 (5) : 22-27, 2014.
10) Tremaroli V, Backhed F : Functional interactions between the gut microbiota and host metabolism. Nature 489 (7415) : 242-249, 2012.

最近チェックした商品履歴

Loading...